Literature DB >> 28752639

Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices.

E J Neufeld1, L Solimeno2, D Quon3, C Walsh4, S Seremetis5, D Cooper5, N N Iyer5, C S Hoxer6, P Giangrande7.   

Abstract

BACKGROUND: While there is substantial literature addressing the principles of general management of haemophilia, literature on perioperative management of haemostasis is scarce.
OBJECTIVE: The aim of this study was to better understand perioperative management among congenital haemophilia B patients (without inhibitors) and to gain insights into real-world surgical practices.
METHOD: A systematic literature review, with an emphasis on haemophilia B, was conducted using EMBASE® , Medline® and the Cochrane Library. Studies from 1974 to June 2015 were accessed, and 132 studies were eligible for the full-study review. An international expert panel with five haematologists and one surgeon reviewed the resulting literature and provided further insights.
RESULTS: The literature review revealed that documented experience in the perioperative management of bleeding risk in haemophilia B patients is relatively scarce. Therefore, the review was amended to provide a comprehensive overview of the perioperative management for haemophilia A and B patients; the expert panel applied a particular focus to haemophilia B. Several gaps were identified in the literature including the lack of consensus on defining surgery in terms of bleeding risk, optimal factor levels during surgery and lack of robust evidence on surgical outcomes. The ensuing discussions with the expert panel provided validation of some of the results from the systematic literature review and proposed future directions for perioperative management. Suggestions included collaboration with haemophilia treatment centres (HTCs) to collect real-world data on perioperative management, establishing the need for optimal factor level monitoring practice, and the appropriate adoption of extended half-life products in clinical settings.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  expert panel; guideline; haemophilia B; literature review; replacement therapy; surgery

Mesh:

Substances:

Year:  2017        PMID: 28752639     DOI: 10.1111/hae.13279

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors.

Authors:  Sreenivas P Veeranki; Priti Pednekar; Marlon Graf; Rifat Tuly; Michael Recht; Katharine Batt
Journal:  J Blood Med       Date:  2021-10-21

2.  Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report.

Authors:  Jan-Paul Bohn; Anna Fiala; Sebastian Bachmann; Christian Irsara; Dominik Wolf; Clemens Feistritzer
Journal:  Ther Adv Hematol       Date:  2022-07-26

Review 3.  GlycoPEGylated recombinant factor IX for hemophilia B in context.

Authors:  Elena Santagostino; Maria Elisa Mancuso
Journal:  Drug Des Devel Ther       Date:  2018-09-11       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.